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Several lines of evidence suggest that anxiety plays a key role in the development and 
maintenance of anorexia nervosa (AN) in children. The purpose of this study was to 
examine cortical GABA(A)-benzodiazepine receptor binding before and after treatment 
in children beginning intensive AN treatment. Brain single-photon emission computed 
tomography (SPECT) measurements using 123I-iomazenil, which binds to GABA(A)-
benzodiazepine receptors, was performed in 26 participants with AN who were enrolled 
in a multimodal treatment program. Sixteen of the 26 participants underwent a repeat 
SPECT scan immediately before discharge at conclusion of the intensive treatment 
program. Eating behavior and mood disturbances were assessed using Eating Attitudes 
Test with 26 items (EAT-26) and the short form of the Profile of Mood States (POMS). 
Clinical outcome scores were evaluated after a 1-year period. We examined association 
between relative iomazenil-binding activity in cortical regions of interest and psychomet-
ric profiles and determined which psychometric profiles show interaction effects with 
brain regions. Further, we determined if binding activity could predict clinical outcome 
and treatment changes. Higher EAT-26 scores were significantly associated with lower 
iomazenil-binding activity in the anterior and posterior cingulate cortex. Higher POMS 
subscale scores were significantly associated with lower iomazenil-binding activity in the 
left frontal, parietal cortex, and posterior cingulate cortex (PCC). “Depression–Dejection” 
and “Confusion” POMS subscale scores, and total POMS score showed interaction 
effects with brain regions in iomazenil-binding activity. Decreased binding in the anterior 
cingulate cortex and left parietal cortex was associated with poor clinical outcomes. 
Relative binding increases throughout the PCC and occipital gyrus were observed after 
weight gain in children with AN. These findings suggest that cortical GABAergic receptor 
binding is altered in children with AN. This may be a state-related change, which could 
be used to monitor and guide the treatment of eating disorders.
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FigUre 1 | Flow diagram of the study. AN, anorexia nervosa; EAT26, 
Eating Attitude Test with 26 items; POMS, Profile of Mood States; WISC-III, 
Wechsler Intelligence Scale for Children; SPECT, single-photon emission 
computed tomography; N.A., not available. Bidirectional thin arrows indicate 
statistical comparisons or correlation analyses between objects.
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inTrODUcTiOn
Anorexia nervosa (AN) typically presents in females during ado-
lescence. It is a serious psychiatric illness conferring substantial 
morbidity and mortality, which manifests as disturbances in eat-
ing habits, excessive preoccupation with weight, restricted caloric 
intake, and body image distortion (1). Although some research 
regarding the outcome of childhood AN is encouraging in terms 
of mortality and recovery from AN (2), long-term comorbid 
psychiatric disorders, such as anxiety disorders and affective 
disorders, represent unfavorable prognostic factors (3). Anxiety 
is present in the majority of children with AN prior to abnormal 
eating or body image distortions (4). Anxiety in children with AN 
is also associated with decreased body mass index (BMI) (5, 6). 
Moreover, trait anxiety scales in children show significant positive 
correlations with eating disorder psychopathology such as “drive 
for thinness,” “body dissatisfaction,” and “perfectionism” (5).
Several lines of evidence implicate gamma-aminobutyric acid 
(GABA)ergic neurotransmission in the pathophysiology of anxi-
ety (7). Recently, a large-scale candidate gene study found that 
allele frequency differences in the GABA receptor SNP, GABRG1, 
are related to levels of trait anxiety in AN and bulimia nervosa (8). 
Furthermore, elevated GABA(A) receptor levels in the amygdala 
were reported in activity-based anorexia (ABA), an animal model 
of the behavioral phenotype of AN (9). Upregulated GABA(A) 
receptor function may be associated with anxiety in ABA animals. 
Several neuroimaging studies have shown negative correlations 
between GABA-benzodiazepine receptor binding activity and 
severity of anxiety symptoms in adults with panic or traumatic 
disorders (10, 11). However, to date, no study has examined 
GABA(A) receptor binding or function in AN. It is possible that 
GABAergic neurons may play an important role in both premor-
bid anxiety of AN and the pathogenesis of childhood AN.
Single-photon emission computed tomography (SPECT) is a 
nuclear medicine tomographic modality employing gamma rays, 
and in which, injected radionuclides are attached to ligands selec-
tive for specific receptors of interest. 123I-iomazenil is a radioactive 
ligand for central-type benzodiazepine receptors, which form a 
complex with GABA(A) receptors. Thus, 123I-iomazenil SPECT 
measures GABA(A) receptor binding and indirectly assays 
GABA(A) receptor function. 123I-iomazenil is a frequently used 
radionuclide tracer for presurgical evaluation of patients with 
refractory partial epilepsy (12). Moreover, recent neuroimaging 
studies have explored the role of GABAergic inhibitory function 
in psychiatric disorders, such as schizophrenia, Alzheimer’s dis-
ease, and developmental disorders, as well as anxiety disorders 
including panic and traumatic stress disorders (10, 11, 13–17). In 
these reports, significant correlations between GABAergic func-
tion and dimensional scales measuring anxiety, panic, negative 
cognitions, and psychiatric status were found.
The aims of this study were to (1) determine if GABA(A) 
receptor binding is associated with AN symptoms and anxiety in 
children initiating clinical treatment for AN; (2) determine which 
brain regions are involved; (3) determine if measures of GABA(A) 
receptor binding can predict a participant’s clinical outcome; and 
(4) determine if these measures change with successful treatment. 
We hypothesized that lower cortical iomazenil-binding activity 
is associated with greater baseline symptom severity and poor 
clinical outcome in children with AN.
MaTerials anD MeThODs
Participants
The study complies with the Declaration of Helsinki and informed 
consent was obtained from participants and parents or legal guard-
ians prior to enrollment in the imaging study. The procedures for 
assent, informed consent, and study design were approved by 
the Medical Ethical Committee of Kurume University School of 
Medicine. Twenty-six female participants were recruited who ful-
filled the Diagnostic and Statistical Manual of Mental Disorders, 
4th Edition (DSM-IV) criteria for AN, and had been admitted 
to the Department of Pediatrics, Kurume University School of 
Medicine between 2007 and 2012 for clinical treatment in an 
eating disorders program. All were restricted-type AN. The flow 
diagram for the study is shown in Figure 1. The eating disorder 
treatment program has a multimodal approach, which includes 
parenteral nutrition, psychotherapy, and behavioral interven-
tion. On initiation of treatment, participants and families have 
extensive psychoeducation focused on major physical risk factors 
associated with restricted body weight and therapeutic goals for 
hospitalization. Individual behavior therapy with reward rein-
forcement is used to facilitate recovery. Although oral feeding was 
sufficient for the majority of participants, parenteral nutrition was 
implemented for select participants with severe AN. Behavioral 
therapy was combined with nutritional counseling and individual 
psychotherapy to target difficult emotions and family relational 
FigUre 2 | Designated regions of interest (rOis) in fusion images of 
123i-iomazenil sPecT and Mri. The top panel shows brain MRI (transverse 
and sagittal T1 sequences), the middle panel the corresponding results of 
123I-iomazenil SPECT, and the bottom panel fusion imaging. Outlined regions 
in the bottom panel indicate designated ROIs, namely, (a) the superior frontal, 
(b) parietal, (c) frontal, (d) middle temporal, and (e) occipital regions; (f) 
anterior and (g) posterior cingulate gyrus.
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stress. As part of the treatment, participants completed the Eating 
Attitude Test (EAT-26), a standardized, self-report measure of 
eating disorder symptoms, which is widely used for screening 
and measurement of symptoms and characteristics of eating 
disorders (18). Participants rated their mood using the short form 
of the Profile of Mood States (POMS), a validated measure that 
consists of 30 items describing six moods: “Tension–Anxiety,” 
“Depression–Dejection,” “Anger–Hostility,” “Vigor,” “Fatigue’, and 
“Confusion” (19). High Vigor scores reflect a good mood or emo-
tion, and low scores in the other subscales reflect a good mood 
or emotion. Total mood disturbance (TMD) was obtained by 
subtraction of the Vigor score from the sum of Tension–Anxiety, 
Depression–Dejection, Anger–Hostility, Fatigue, and Confusion 
scores. Each original POMS score was converted to a T-score 
(20). We selected the POMS for measurement of anxiety, as we 
have neither a Japanese version of State-Trait Anxiety Inventory 
for Children (STAIC) nor other validated Japanese psychometric 
scales for anxiety. Upon enrollment in the study, a diagnosis of AN 
and comorbidities was confirmed in all participants by semi-struc-
tured interviews using the Mini-International Neuropsychiatric 
Interview (MINI) (21), which were performed by two psychiatrists 
(Michiko Matsuoka and Hiromi Chiba). All participants under-
went cognitive assessment using the Wechsler Intelligence Scale 
for Children (WISC-III). Psychometric profiles were performed 
before treatment. Participants were medication naïve and did not 
receive pharmacological treatment during the course of the study. 
Twenty-three participants had secondary amenorrhea and three 
had not yet reached menarche. In all participants, brain magnetic 
resonance imaging (MRI) examination was performed on admis-
sion to identify any structural abnormalities, e.g., regional brain 
atrophy. Participants with severe, co-occurring medical illnesses 
(such as superior mesenteric artery syndrome) were excluded. 
Ethical concern regarding the use of ionizing radiation in healthy 
children precluded the enrollment of a control group for this study.
clinical Outcome Measures
Follow-up clinical assessments were performed 1  year after 
hospital discharge by one pediatrician (Shinichiro Nagamitsu) 
and two psychiatrists (Michiko Matsuoka and Hiromi Chiba). A 
structured approach was used to define clinical outcome a priori. 
Clinical outcome score was based on eight items, as defined 
in prior work (22). This included weight change, menstrual 
status, abnormal eating behavior, body image, binge eating or 
purging behaviors, insight, school attendance, and quality of 
family relationship. Improved or impaired answers were scored 
“0” and “1,” respectively. For items of weight change and school 
attendance, improved and unimproved ratings were scored “0” 
and “2,” respectively. The middle score “1” indicates “unchanged 
condition.” The outcome was considered good with total scores 
less than “4” and poor with total scores of “4” or over. The clinical 
outcome raters (Shinichiro Nagamitsu, Michiko Matsuoka, and 
Hiromi Chiba) were blinded regarding SPECT data.
iomazenil sPecT
All 26 children underwent brain imaging using SPECT. The 
first 123I-iomazenil SPECT examination was performed before 
treatment and the second one immediately before discharge (16 
of 26 participants). Mean duration between the first and second 
SPECT examinations was approximately 4 months. Briefly, par-
ticipants were injected intravenously with a bolus of 95–117 MBq 
123I-iomazenil (Nihon Medi-Physics Co., Tokyo, Japan), which 
binds with high affinity to the GABA(A)-benzodiazepine recep-
tor. The SPECT scan was performed 3 h after injection of the tracer 
without any sedation, using a large field-of-view dual-detector 
camera and a computer system equipped with a low-energy, high-
resolution, and parallel-hole collimator. The dual detector camera 
rotated over 180° in a circular orbit and in 32 steps of 40 s each to 
cover 360° in approximately 22 min.
image and statistical analyses
Images of 123I-iomazenil scintigraphs were analyzed by three-
dimensional stereotactic surface projections (3D-SSP) using 
iSSP3 software (Nihon Medi-Physics Co.). Stereotactic ana-
tomical standardization was performed as described previously 
(23). Briefly, rotational correction of the SPECT data set and 
three-dimensional centering were performed, followed by rea-
lignment to the anterior commissure–posterior commissure line. 
Differences in individual brain size were accounted for by linear 
scaling and regional anatomical differences minimized using a 
non-linear warping technique (24). Consequently, each brain was 
anatomically standardized to match a standard atlas brain. Brain 
MRI was performed using a superconducting magnet operating 
at 1.5  T. For coregistered SPECT and MRI analysis, a method 
of image integration was applied using Fusion Viewer software 
(Nihon Medi-Physics Co.) with a registration algorithm based on 
maximum mutual information (Figure 2). Subsequently, cortical 
and subcortical regions of interest (ROIs) in the acquired SPECT 
TaBle 1 | clinical characteristics and POMs scores for subjects with 
relative iomazenil-binding activity in each brain region.
Before treatment (1st sPceT) after treatment 
(2nd sPceT)
all subjects subjects having 
2nd sPecT
N 26 16 16
Age 14.1 ± 1.3 14.4 ± 1.1 14.8 ± 1.1
BMI 13.7 ± 2.0 13.3 ± 1.6 15.7 ± 0.9
BMI-SDS −3.7 ± 1.9 −4.1 ± 1.9 −2.3 ± 1.1
EAT-26 22.4 ± 12.0
Menstrual cycle
 Not experienced 2
 Secondary 
amenorrhea
22
POMS
 Tension–Anxiety 46.1 ± 10.3
 Depression–Dejection 53.1 ± 11.8
 Anger–Hostility 50.3 ± 11.9
 Vigor 43.4 ± 11.8
 Fatigue 47.4 ± 11.4
 Confusion 52.1 ± 15.5
 Total score 205.6 ± 59.4
 WISC-III 105 ± 13
Relative iomazenil-binding activities
 R superior frontal 1.41 ± 0.11 1.40 ± 0.11 1.45 ± 0.12
 L superior frontal 1.44 ± 0.15 1.45 ± 0.13 1.48 ± 0.16
 R parietal 1.46 ± 0.14 1.48 ± 0.14 1.50 ± 0.14
 L parietal 1.51 ± 0.16 1.55 ± 0.15 1.53 ± 0.13
 R middle frontal 1.41 ± 0.11 1.41 ± 0.11 1.46 ± 0.10
 L middle frontal 1.45 ± 0.14 1.47 ± 0.14 1.52 ± 0.12
 R middle temporal 1.46 ± 0.12 1.46 ± 0.12 1.54 ± 0.12*
 L middle temporal 1.44 ± 0.14 1.47 ± 0.14 1.54 ± 0.11*,†
 R occipital 1.74 ± 0.14 1.78 ± 0.14 1.88 ± 0.26*
 L occipital 1.77 ± 0.20 1.79 ± 0.19 1.88 ± 0.21‡
 Anterior cingulate 1.44 ± 0.13 1.47 ± 0.12 1.59 ± 0.24*,†
 Posterior cingulate 1.65 ± 0.17 1.69 ± 0.16 1.80 ± 0.33‡
SPECT, single-photon emission computed tomography; BMI, body mass index; 
EAT-26, Eating Attitude Test with 26 items; POMS, Profile of Mood States; WISC-III, 
Wechsler Intelligence Scale for Children; R, right; L, left.
*Significant difference compared with all subjects (P < 0.05).
†Significant difference compared with subjects at second SPECT (P < 0.05).
‡Trend toward significance in all subjects (P < 0.1).
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data were defined. Using elliptical templates, ROIs were drawn 
manually for the major cortical and subcortical brain regions in 
a representative subject. To eliminate the disadvantage of lower 
reliability with manual operations, the same elliptical templates 
were used to define ROIs in other subjects. ROIs were placed over 
the following regions: superior frontal, middle frontal, parietal, 
middle temporal, and occipital regions; the cerebellum in each 
hemisphere; and the anterior and posterior cingulate cortex 
(ACC and PCC, respectively; Figure 2). Two neuroradiologists 
(Hitoshi Tanigawa and Masatoshi Ishibashi), blinded to clinical 
symptoms, independently drew ROIs. Each relative iomazenil-
binding activity in ROIs was expressed as a ratio of that in the 
cerebellum, as patients with AN have no cerebellar symptoms. 
Spearman’s correlation was used to determine correlations 
between relative iomazenil binding in each region on baseline 
SPECT scan and age, BMI-standard deviation score (BMI-SDS), 
EAT-26, and POMS subscale score. To test for possible differential 
relationships between POMS and iomazenil-binding activity in 
brain regions, the brain regions were classified into three groups: 
center region, left hemisphere region, and right hemisphere 
region. ROIs were grouped accordingly: ACC and PCC as the 
center region; left of superior frontal, parietal, frontal, temporal, 
and occipital as the left hemisphere region; and right of superior 
frontal, parietal, frontal, temporal, and occipital as the right 
hemisphere region. POMS subscales were separately analyzed 
using the mixed-effect model (SAS 9.3 PROC MIXED). Regions, 
POMS subscale, and their interactions were treated as fixed effects 
in the model, while the intercept was treated as a random effect, 
therefore accounting for correlations among iomazenil-binding 
activities. When the interaction between all three regions and 
POMS subscale was significant, ROIs were analyzed within the 
region and POMS using mixed model regression to determine 
significances between ROIs. The Mann–Whitney U test was used 
to compare between participants with good and poor outcomes.
Neurological Statistical Image Analysis software (NEUROSTAT, 
Stat_1tZ), which can perform a paired t test between two cor-
responding groups using cross-sectional images, was adopted 
to examine changes in iomazenil binding between the first and 
second SPECT. Statistical significance was set at Z-score >2, a 
level commonly used to discriminate abnormalities. The regions 
identified were transformed into three-dimensional anatomical 
data and Talairach coordinates to show brain landmarks.
resUlTs
Participants’ characteristics
The mean and SD of age before treatment was 14.1 (1.3) years 
of age (range, 10.5–15.6 years of age) (Table 1). Mean (SD) BMI 
before and after treatment were 13.7 (2.0) and 15.7 (0.9), respec-
tively. Mean (SD) BMI-SDS before and after treatment were −3.7 
(1.9) and −2.3 (1.1), respectively. Mean (SD) EAT-26 score before 
therapy was 22.4 (12.0), which was higher compared with the 
reference control value (25). Five participants had co-occurring 
psychiatric disorders including two with autism spectrum 
disorders, one with learning disability, and two with selective 
mutism. Mean (SD) scores for each of the POMS subscales were 
46.1 (10.3) for Tension–Anxiety, 53.1 (11.8) for Depression–
Dejection, 50.3 (11.9) for Anger–Hostility, 43.4 (11.8) for Vigor, 
47.4 (11.4) for Fatigue, and 52.1 (15.5) for Confusion. Mean (SD) 
score for TMD of POMS was 205.6 (59.4). The subscale scores 
of Tension–Anxiety and Depression–Dejection were higher than 
normal ranges (26), but the differences did not reach significance. 
Mean (SD) IQ was 105 (13). None of the participants showed 
regional brain atrophy on brain MRI examination. Mean dura-
tion of hospitalization was approximately 4 months. Mean (SD) 
age on the second SPECT examination was 14.8 (1.1). The range 
of duration between the first and second SPECT was from 86 to 
250 days (mean, 128 days).
Participants’ Outcome
Clinical outcome scores 1 year after treatment were examined in 
20 out of 26 participants. Three participants did not complete the 
TaBle 2 | correlation coefficients between POMs subscale scores, eaT-26, and iomazenil-binding activity in each brain region from the first sPecT.
Ta D ah V F c Total eaT-26
R superior frontal 0.036 0.290 −0.034 −0.014 0.161 0.097 0.116 −0.203
L superior frontal −0.473* −0.428* −0.494* 0.155 −0.332 −0.646** −0.530* −0.338
R parietal 0.022 0.312 −0.037 −0.057 0.019 −0.001 0.073 −0.100
L parietal −0.413* −0.250 −0.414* −0.029 −0.314 −0.604** −0.417* −0.338
R frontal −0.213 0.057 −0.179 −0.073 0.054 −0.094 −0.061 −0.431
L frontal −0.498* −0.320 −0.468* 0.100 −0.288 −0.598** −0.476* −0.390
R temporal −0.095 0.226 −0.241 −0.144 0.015 −0.009 0.009 −0.151
L temporal −0.210 −0.130 −0.367 −0.040 −0.101 −0.374 −0.245 −0.141
R occipital −0.175 0.003 −0.356 −0.111 −0.162 −0.222 −0.168 −0.109
L occipital −0.0355 −0.378 −0.510* 0.027 −0.288 −0.589** −0.454* −0.097
Anterior cingulate −0.043 −0.008 −0.034 −0.277 −0.016 −0.156 −0.005 −0.606**
Posterior cingulate −0.553* −0497* −0.476* 0.262 −0.440* −0.641** −0.594* −0.312
POMS, Profile of Mood States; TA, Tension–Anxiety; D, Depression–Dejection; AH, Anger–Hostility; V, Vigor; F, Fatigue; C, Confusion; EAT-26, Eating Attitude Test with 26 items.
*P < 0.05 and **P < 0.01 indicate significant correlations.
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treatment. It was not possible to examine three other participants, 
as two were transferred to locked psychiatric units and one was 
transferred to a local hospital. After the evaluations, 13 partici-
pants were classified as having a good outcome and 7 with a poor 
outcome.
Baseline correlations between 
123i-iomazenil Binding and clinical 
Measures
Relative iomazenil-binding activities in each brain region are 
summarized in Table  1. There were significant associations 
between some clinical measures and relative iomazenil-binding 
activity in several brain regions. Higher EAT-26 scores were sig-
nificantly associated with lower iomazenil-binding activity in the 
ACC (Table 2). Higher “Tension–Anxiety” score at the beginning 
of therapy was significantly associated with lower iomazenil-
binding activity in the left superior frontal, parietal, middle 
frontal cortex, and PCC (Table  2). Higher “Anger–Hostility,” 
“Confusion,” and “Total” scores at the beginning of therapy 
were significantly associated with lower iomazenil-binding 
activity in the same regions and left occipital cortex (Table 2). 
Furthermore, “Depression–Dejection” and “Fatigue” scores were 
also significantly associated with lower iomazenil-binding activ-
ity in the PCC (Table  2). There were no associations between 
BMI-SDS and iomazenil-binding activity in any brain region. 
However, there were significant positive correlations between 
age and iomazenil-binding activity in the left and right middle 
frontal, left parietal, and PCC (r = 0.415, 0.392, 0.430, and 0.454, 
respectively, P < 0.05) (data not shown).
interactions between POMs subscales 
and Brain regions in iomazenil-Binding 
activity
The mixed-effect model detected significant interaction effects 
between three main brain regions and POMS total scale and sub-
scales of “Depression–Dejection” and “Confusion” (Table 3). In 
the three main brain regions, significant differences were identi-
fied between the left and right hemisphere regions on POMS total 
score and subscales of “Depression–Dejection” and “Confusion” 
(Table 4). Furthermore, significant differences between left and 
right hemisphere regions were identified in the superior frontal 
region on POMS total score (t = −2.63, P =  0.0094), superior 
frontal and occipital regions on the subscale of “Confusion” 
(t = −3.16, P = 0.0018; t = −3.49, P = 0.0062, respectively), and 
superior frontal region on the subscale of “Depression–Dejection” 
(t = −2.75, P = 0.0065). This finding remained significant after 
Bonferroni correction for multiple comparisons (P = 0.01).
comparison of 123i-iomazenil-Binding 
activity Before and after Treatment
Relative iomazenil-binding activity after treatment was signifi-
cantly increased in the ACC, right occipital, and bilateral middle 
temporal gyrus (Table 1). Comparisons of adjusted iomazenil-
binding activity before and after weight gain were examined in the 
same 16 participants using NEUROSTAT. There were significant 
increases in iomazenil-binding activity after treatment in the ACC, 
PCC, frontal gyrus, occipital gyrus, and hippocampus (Figure 3). 
By contrast, there was a significant decrease in iomazenil-binding 
activity after treatment in the bilateral inferior temporal cortex 
(data not shown). The Talairach coordinates of sites with Z-scores 
>3.0 are listed with the associated brain regions in Table 5.
association between 123i-iomazenil-
Binding activity in the acc and clinical 
Outcome
There was a significant baseline difference in iomazenil-binding 
activity between participants with good and poor clinical out-
come scores in the ACC (1.48 ± 0.09 vs. 1.32 ± 0.12, respectively, 
P <  0.05) (Figure  4) and left parietal gyrus (1.57 ±  0.12 vs. 
1.40 ± 0.15, respectively, P < 0.05). Relative baseline iomazenil-
binding activity in the ACC and left parietal gyrus in participants 
with a poor clinical outcome were significantly lower than those 
with a good clinical outcome.
DiscUssiOn
To our knowledge, this is the first investigation on SPECT 
123I-iomazenil brain imaging in children with AN. Using SPECT 
FigUre 3 | image analysis (1tZ) of increased iomazenil-binding changes before and after weight gain in the brain of children with an. Significant 
increases in iomazenil-binding activity before and after weight gain are shown in the anterior and posterior cingulate cortex, occipital cortex, frontal cortex, and 
hippocampus, as indicated by the bright orange color.
TaBle 3 | interaction effects between POMs subscales and three main 
regions (center, left, and right hemispheres).
POMs subscales df (between 
regions)
df (within 
regions)
F P-value
POMS total 2 194 3.52 <0.05*
Tension–Anxiety 2 194 2.07 0.13
Depression–Dejection 2 194 4.09 <0.05*
Anger–Hostility 2 194 2.16 0.12
Vigor 2 194 0.22 0.8
Fatigue 2 193 1.49 0.23
Confusion 2 194 5.65 <0.01*
POMS, Profile of Mood States.
*Indicates significance.
TaBle 4 | interaction between three regions and POMs subscales.
POMs total confusion Depression–
dejection
t P-value t P-value t P-value
Center–left 0.88 0.38 −1.22 0.22 −0.5 0.62
Center–right −1.12 0.27 −1.32 0.19 −1.61 0.11
Left–right 2.65 0.0087* 3.36 <0.001* 2.79 0.0057*
*indicates significance.
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123I-iomazenil brain imaging, we found association between corti-
cal GABAergic receptor binding and clinical manifestations of 
childhood AN. Higher EAT-26 and mood disturbance scores were 
significantly associated with lower GABAergic inhibitory binding 
in various brain regions. Poor clinical outcome was also associated 
with lower GABAergic receptor binding in the ACC and left pari-
etal region. GABAergic receptor binding was mainly activated in 
the ACC, PCC, frontal gyrus, and occipital gyrus after treatment.
We found significant correlation between reduced 
GABAergic receptor binding in various brain regions and 
mood disturbances, as assessed using POMS subscales. Mixed 
model regression showed significant effects for the interactions 
between brain regions and POMS total scale and subscales of 
“Depression–Dejection” and “Confusion.” Furthermore, the 
effect of these POMS profiles showed significantly different 
binding activities between the left and right hemispheres, espe-
cially in the superior frontal region. These results indicate that 
GABAergic neuronal activity correlates to mood disturbances 
in children with AN. The potential involvement of GABAergic 
neurotransmission in the pathophysiology of AN was recently 
investigated by genetic allele frequency analysis of GABRG1 in 
AN patients. This study showed significant correlation between 
specific allele frequency in this GABA receptor SNP and levels 
of trait anxiety in the patients (8). Further, in an animal model of 
AN, elevated GABA(A) receptor expression in the amygdala was 
associated with increased anxiety (9). It remains unclear whether 
GABA(A) receptor function is associated with the underlying 
pathophysiology of childhood AN or a result of long-term star-
vation. However, a relative strength of our present findings is 
that at repeat SPECT scan, the participants were not completely 
weight-restored [mean BMI 15.7 (0.9 SD)], suggesting that 
changes in brain 123I-iomazenil binding may be related to clinical 
improvement rather than mere weight restoration. Nonetheless, 
this does suggest that GABAergic receptor-mediated inhibitory 
function may be associated with mood disturbances in children 
with AN.
We also found a significant negative correlation between 
123I-iomazenil-binding activity in the ACC and abnormal eating 
attitude described by EAT-26 score, with a greater decrease in 
activity in the ACC of AN children with poor clinical outcomes, 
FigUre 4 | relative iomazenil-binding activity in the anterior 
cingulate gyrus in participants with different clinical outcomes. 
Relative iomazenil-binding activity in the anterior cingulate gyrus at initiation of 
treatment in participants with good clinical outcomes was significantly higher 
than those with poor clinical outcomes.
TaBle 5 | Brain regions and Talairach coordinates showing significantly 
increased and decreased iomazenil binding in children with anorexia 
nervosa before and after weight gain.
regions Talairach coordinates P-value
X Y Z Z score
Increased regions
 Right anterior cingulate gyrus 3 −19 36 6.33 <0.00001
 Right occipital gyrus 17 −103 −4 5.43 <0.00001
 Left medial frontal gyrus −1 19 −14 4.89 <0.00001
 Left occipital gyrus −1 −94 2 4.31 <0.00001
 Right posterior cingulate gyrus 6 −40 22 3.99 <0.00005
 Right parahippocampal gyrus 26 −31 −25 3.84 <0.0001
 Right medial frontal gyrus 3 29 4 3.84 <0.0001
Decreased regions
 Right inferior temporal gyrus 55 −24 −9 4.28 <0.00001
 Left inferior temporal gyrus −53 −19 −14 3.05 <0.01
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compared with those with good clinical outcomes. Furthermore, 
binding activity in the ACC was significantly increased after 
treatment. As the present clinical outcome score was composed 
of current BMI and presence of menstruation, as well as changes 
of eating behavior and social interaction, GABAergic functional 
activity in the ACC may be related to biological vulnerability 
of recovery from AN symptoms. Converging lines of evidence 
suggest correlations between morphological or functional neural 
changes and differential clinical outcomes in AN. For example, 
McCormick et  al. (27) reported that although the dorsal ACC 
gray matter volume is significantly reduced in patients with AN 
compared with normal controls, greater normalization of the right 
dorsal ACC volume following weight restoration prospectively 
predicted sustained remission at 1  year post-hospitalization. 
Functional MRI studies have shown that increased activation 
in the dorsal ACC and prefrontal cortex in response to food 
stimuli differentiates recovered AN patients from chronically 
ill AN patients (28). Further, subcallosal cingulate deep brain 
stimulation has recently been applied as a treatment strategy 
for treatment-refractory AN and associated with improvement 
in mood, anxiety, affective regulation, and increased BMI (29). 
Taken together, our findings contribute to emerging evidence that 
variations in functional activities of the ACC may be predictors 
of outcomes of AN.
Similar to the ACC, neural activities in the PCC may play 
important roles in the pathophysiology of AN. The PCC is func-
tionally coupled with other brain regions as a default mode net-
work and involved in self-related aspects of cognitive processing 
such as self-reference and self-reflection (30). Functional brain 
imaging suggests that dysfunction in resting-state functional 
connectivity in regions involved in self-referential processing 
might be associated with development of AN (31). Further, 
several lines of evidence show that less activation in the PCC is 
associated with altered inhibitory processing, which might rep-
resent a behavioral characteristic and impairment of emotional 
processing in AN (32, 33). In the present study, several higher 
mood disturbance scores were significantly associated with lower 
GABAergic inhibitory binding, mainly in the PCC. Similarly, the 
PCC was one of the brain regions in which iomazenil-binding 
activity increased after treatment. In a previous neuroimaging 
study in children with AN, increased cerebral blood flow (CBF) 
was observed in the parietal cortex and PCC after inpatient 
treatment (34). Taken together, increased GABAergic inhibitory 
function in the PCC after weight gain in our study might indicate 
improved self-referential processing and cognitive control, which 
were missing during their starvation period.
We found evidence of increased 123I-iomazenil-binding activ-
ity in the occipital cortex after treatment in children with AN. In 
general, iomazenil-binding activity is strongest in the occipital 
cortex, indicating that GABA receptors are densely distributed 
in this area. GABA is involved in interocular suppression in the 
visual cortex and plays a central role in determining visual cortex 
selectivity (35). As the brain has a limited capacity, attention 
allows relevant incoming information to be selectively enhanced 
while suppressing irrelevant information, the processing for 
which may be modulated by GABAergic inhibitory function 
(36, 37). A recent MR spectroscopy study revealed negative cor-
relation between the amount of occipital GABA and cognitive 
failure in healthy patients, indicating that the inhibitory capacity 
in sensory areas affects their ability to ignore information that 
is irrelevant to current behavioral goals (37). In AN patients, 
cognitive deficits in impaired visuospatial ability, impaired 
complex visual memory, and impaired selective attention have 
been reported (38, 39). As GABA plays an important part in 
stimulus processing and suppression in sensory areas, increased 
GABAergic inhibitory activation observed in the occipital cortex 
in AN participants in our study may reflect enhanced suppres-
sion of visual information processing, possibly resulting in the 
improvement of cognitive deficits.
The present study has several limitations that require consid-
eration in future studies. First, brain imaging data from normal 
healthy children are not available because ethics approval was not 
feasible for SPECT studies in healthy control children. Therefore, 
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we focused our research on the correlation between GABAergic 
inhibitory function in brain regions and psychometric profiles, 
and changes in these functions before and after treatment 
in AN participants. Thus, we could not determine if the basic 
GABAergic inhibitory function is upregulated or downregulated, 
compared to healthy controls. Second, it is possible that changes 
in iomazenil binding after treatment might be associated with 
confounding effects, secondary to starvation and restored body 
weight. However, as the average period for repeat SPECT was short 
(4 months), weight restoration was not complete. Furthermore, 
our previous neuroimaging report regarding CBF changes after 
treatment in AN patients showed no global increase in CBF 
changes except specific brain regions (bilateral parietal lobe and 
PCC) (34). Consequently, confounding effects are unlikely to 
be a cause of our SPECT findings. Third, SPECT exhibits poor 
resolution around some limbic regions, such as the amygdala 
and hippocampus, which are important for emotion processing. 
In these small regions, the obtained radioactivity might differ 
from the true activity because of a partial volume effect (PVE). 
The PVE can be defined as underestimation of binding per unit 
brain volume in small objects or regions because of blurring of 
radioactivity (spill-out and spill-in) between regions (40, 41). 
These regions need to be resolved using MR imaging-based cor-
rection for PVE. Fourth, we did not examine the participants’ 
psychometric profiles at the end of hospitalization. Although the 
majority of participants obtained proper eating habits, attended 
school, and improved parental relationships by the discharge 
period, these socio-emotional behaviors were not evaluated 
using the psychometric profile. To confirm our understanding of 
altered 123I-iomazenil-binding activity due to therapeutic inter-
vention, improvement of socio-emotional difficulties should be 
consecutively measured.
In conclusion, GABAergic inhibitory receptor function in the 
brain may play an important role in manifesting clinical symp-
toms of childhood AN. Lower GABAergic 123I-iomazenil binding 
in specific brain regions at initiation of treatment is associated 
with clinical severity of mood disturbances and abnormal eating 
attitude in this sample of participants. Decreased binding in the 
ACC and left parietal cortex were associated with poor clinical 
outcomes. Conversely, increased changes in GABAergic receptor 
binding in the ACC, PCC, and occipital gyrus might be important 
for the recovery process of childhood AN. Although GABAergic 
function in the cingulate cortex might be evaluated as a potential 
predictor of clinical outcome, it will be important to determine the 
association between function and long-term prognosis. Further 
research focused on GABAergic receptor-mediated function 
among participants with eating disorders is warranted.
aUThOr cOnTriBUTiOns
SN participated in the design of this study and compiled the man-
uscript. SN, MM, HC, SO, and YY saw the patients and obtained 
informed consent and their agreement to participate in the study. 
Three radiologists (HT, HK, and MI) were in charge of radioac-
tive measurements and calculations of iomazenil activity using 
ROIs. RS and TK, statistician, conducted the statistical analyses. 
PC and TM supervised the preparation of the manuscript.
acKnOWleDgMenTs
This work was supported by grants from the Ministry of 
Education, Culture, Sports, Science, and Technology (#22591143 
and #25460643) and Ministry of Health, Labour and Welfare, 
(#14428000).
reFerences
1. Fairburn CG, Harrison PJ. Eating disorders. Lancet (2003) 361:407–46. 
doi:10.1016/S0140-6736(03)12378-1 
2. Wentz E, Gillberg IC, Anckarsäter H, Gillberg C, Råstam M. Adolescent-
onset anorexia nervosa: 18-year outcome. Br J Psychiatry (2009) 194:168–74. 
doi:10.1192/bjp.bp.107.048686 
3. Saccomani L, Savoini M, Cirrincione M, Vercellino F, Ravera G. Long-term out-
come of children and adolescents with anorexia nervosa: study of comorbidity. 
J Psychosom Res (1998) 44:565–71. doi:10.1016/S0022-3999(97)00210-9 
4. Touchette E, Henegar A, Godart NT, Pryor L, Falissard B, Tremblay RE, et al. 
Subclinical eating disorders and their comorbidity with mood and anxiety 
disorders in adolescent girls. Psychiatry Res (2011) 185:185–92. doi:10.1016/j.
psychres.2010.04.005 
5. Schulze UM, Calame S, Keller F, Mehler-Wex C. Trait anxiety in children 
and adolescents with anorexia nervosa. Eat Weight Disord (2009) 14:163–8. 
doi:10.1007/BF03327817 
6. Dellava JE, Thornton LM, Hamer RM, Strober M, Plotnicov K, Klump KL, 
et al. Childhood anxiety associated with low BMI in women with anorexia 
nervosa. Behav Res Ther (2010) 48:60–7. doi:10.1016/j.brat.2009.09.009 
7. Nemeroff CB. The role of GABA in the pathophysiology and treatment of 
anxiety disorders. Psychopharmacol Bull (2003) 37:133–46. 
8. Bloss CS, Berrettini W, Bergen AW, Magistretti P, Duvvuri V, Strober M, et al. 
Genetic association of recovery from eating disorders: the role of GABA 
receptor SNPs. Neuropsychopharmacology (2011) 36:2222–32. doi:10.1038/
npp.2011.108 
9. Aoki C, Sabaliauskas N, Chowdhury T, Min JY, Colacino AR, Laurino K, et al. 
Adolescent female rats exhibiting activity-based anorexia express elevated 
levels of GABA(A) receptor α4 and δ subunits at the plasma membrane of 
hippocampal CA1 spines. Synapse (2012) 66:391–407. doi:10.1002/syn.21528 
10. Bremner JD, Innis RB, Southwick SM, Staib L, Zoghbi S, Charney DS. 
Decreased benzodiazepine receptor binding in prefrontal cortex in com-
bat-related posttraumatic stress disorder. Am J Psychiatry (2000) 157:1120–6. 
doi:10.1176/appi.ajp.157.7.1120 
11. Cameron OG, Huang GC, Nichols T, Koeppe RA, Minoshima S, Rose D, 
et al. Reduced gamma-aminobutyric acid(A)-benzodiazepine binding sites in 
insular cortex of individuals with panic disorder. Arch Gen Psychiatry (2007) 
64:793–800. doi:10.1001/archpsyc.64.7.793 
12. Higurashi N, Hamano S, Oritsu T, Minamitani M, Sasaki M, Ida H. Iomazenil 
hyperfixation in single photon emission computed tomography study of 
malformations of cortical development during infancy. Eur J Paediatr Neurol 
(2011) 15:372–5. doi:10.1016/j.ejpn.2011.03.007 
13. Busatto GF, Pilowsky LS, Costa DC, Ell PJ, David AS, Lucey JV, et al. Correlation 
between reduced in  vivo benzodiazepine receptor binding and severity of 
psychotic symptoms in schizophrenia. Am J Psychiatry (1997) 154:56–63. 
14. Rissman RA, De Blas AL, Armstrong DM. GABA(A) receptors in 
aging and Alzheimer’s disease. J Neurochem (2007) 103:1285–92. 
doi:10.1111/j.1471-4159.2007.04832.x 
15. Ahn K, Gil R, Seibyl J, Sewell RA, D’Souza DC. Probing GABA receptor 
function in schizophrenia with iomazenil. Neuropsychopharmacology (2011) 
36:677–83. doi:10.1038/npp.2010.198 
16. Oblak AL, Gibbs TT, Blatt GJ. Reduced GABAA receptors and benzodiazepine 
binding sites in the posterior cingulate cortex and fusiform gyrus in autism. 
Brain Res (2011) 1380:218–28. doi:10.1016/j.brainres.2010.09.021 
17. Nagamitsu S, Yamashita Y, Tanigawa H, Chiba H, Kaida H, Ishibashi M, 
et al. Upregulated GABA inhibitory function in ADHD children with child 
February 2016 | Volume 7 | Article 169
Nagamitsu et al. GABA in Children with Anorexia Nervosa
Frontiers in Psychiatry | www.frontiersin.org
behavior checklist-dysregulation profile: 123I-iomazenil SPECT study. Front 
Psychiatry (2015) 6:84. doi:10.3389/fpsyt.2015.00084 
18. Garner DM, Olmsted MP, Bohr Y, Garfinkel PE. The eating attitudes test: 
psychometric features and clinical correlates. Psychol Med (1982) 12:871–8. 
doi:10.1017/S0033291700049163 
19. Yoshihara K, Hiramoto T, Sudo N, Kubo C. Profile of mood states and stress- 
related biochemical indices in long-term yoga practitioners. Biopsychosoc Med 
(2011) 5:6. doi:10.1186/1751-0759-5-6 
20. McNair DM, Lorr M, Droppleman LF. Manual for the Profile of Mood States. 
San Diego: Educational and Industrial Testing Services (1971). 27 p.
21. Otsubo T, Tanaka K, Koda R, Shinoda J, Sano N, Tanaka S, et  al. 
Reliability and validity of Japanese version of the mini-international 
neuropsychiatric interview. Psychiatry Clin Neurosci (2005) 59:517–26. 
doi:10.1111/j.1440-1819.2005.01408.x 
22. Helverskov JL, Clausen L, Mors O, Frydenberg M, Thomsen PH, Rokkedal K. 
Trans-diagnostic outcome of eating disorders: a 30-month follow-up study 
of 629 patients. Eur Eat Disord Rev (2010) 18:453–63. doi:10.1002/erv.1025 
23. Minoshima S, Berger KL, Lee KS, Mintun MA. An automated method for 
rotational correction and centering of three-dimensional functional brain 
images. J Nucl Med (1992) 33:1579–85. 
24. Minoshima S, Koeppe RA, Frey KA, Kuhl DE. Anatomic standardization: 
linear scaling and nonlinear warping of functional brain images. J Nucl Med 
(1994) 35:1528–37. 
25. Rojo-Moreno L, García-Miralles I, Plumed J, Barberá M, Morales MM, Ruiz 
E, et  al. Children’s eating attitudes test: validation in a sample of Spanish 
schoolchildren. Int J Eat Disord (2011) 44:540–6. doi:10.1002/eat.20855 
26. Shibuya I, Nagamitsu S, Okamura H, Ozono S, Chiba H, Ohya T, et  al. 
High correlation between salivary cortisol awakening response and 
psychometric profiles in healthy children. Biopsychosoc Med (2014) 8:9. 
doi:10.1186/1751-0759-8-9 
27. McCormick LM, Keel PK, Brumm MC, Bowers W, Swayze V, Andersen 
A, et  al. Implications of starvation-induced change in right dorsal anterior 
cingulate volume in anorexia nervosa. Int J Eat Disord (2008) 41:602–10. 
doi:10.1002/eat.20549 
28. Uher R, Brammer MJ, Murphy T, Campbell IC, Ng VW, Williams SC, et al. 
Recovery and chronicity in anorexia nervosa: brain activity associated 
with differential outcomes. Biol Psychiatry (2003) 54:934–42. doi:10.1016/
S0006-3223(03)00172-0 
29. Lipsman N, Woodside DB, Giacobbe P, Hamani C, Carter JC, Norwood SJ, 
et  al. Subcallosal cingulate deep brain stimulation for treatment-refractory 
anorexia nervosa: a phase 1 pilot trial. Lancet (2013) 381:1361–70. doi:10.1016/
S0140-6736(12)62188-6 
30. Brewer JA, Garrison KA, Whitfield-Gabrieli S. What about the “Self ” is pro-
cessed in the posterior cingulate cortex? Front Hum Neurosci (2013) 7:647. 
doi:10.3389/fnhum.2013.00647 
31. Cowdrey FA, Filippini N, Park RJ, Smith SM, McCabe C. Increased resting state 
functional connectivity in the default mode network in recovered anorexia 
nervosa. Hum Brain Mapp (2014) 35:483–91. doi:10.1002/hbm.22202 
32. Miyake Y, Okamoto Y, Onoda K, Shirao N, Okamoto Y, Yamawaki S. Brain 
activation during the perception of stressful word stimuli concerning 
interpersonal relationships in anorexia nervosa patients with high degrees 
of alexithymia in an fMRI paradigm. Psychiatry Res (2012) 201:113–9. 
doi:10.1016/j.pscychresns.2011.07.014 
33. Wierenga C, Bischoff-Grethe A, Melrose AJ, Grenesko-Stevens E, Irvine 
Z, Wagner A, et  al. Altered BOLD response during inhibitory and error 
processing in adolescents with anorexia nervosa. PLoS One (2014) 9:e92017. 
doi:10.1371/journal.pone.0092017 
34. Komatsu H, Nagamitsu S, Ozono S, Yamashita Y, Ishibashi M, Matsuishi 
T. Regional cerebral blood flow changes in early-onset anorexia nervosa 
before and after weight gain. Brain Dev (2010) 32:625–30. doi:10.1016/j.
braindev.2009.09.022 
35. Sengpiel F, Vorobyov V. Intracortical origins of interocular suppres-
sion in the visual cortex. J Neurosci (2005) 25:6394–400. doi:10.1523/
JNEUROSCI.0862-05.2005 
36. Desimone R, Duncan J. Neural mechanisms of selective visual attention. Annu 
Rev Neurosci (1995) 18:193–222. doi:10.1146/annurev.ne.18.030195.001205 
37. Sandberg K, Blicher JU, Dong MY, Rees G, Near J, Kanai R. Occipital GABA 
correlates with cognitive failures in daily life. Neuroimage (2014) 87:55–60. 
doi:10.1016/j.neuroimage.2013.10.059 
38. Lask B, Gordon I, Christie D, Frampton I, Chowdhury U, Watkins B. 
Functional neuroimaging in early-onset anorexia nervosa. Int J Eat Disord 
(2005) 37:49–51. doi:10.1002/eat.20117 
39. Weider S, Indredavik MS, Lydersen S, Hestad K. Neuropsychological function 
in patients with anorexia nervosa or bulimia nervosa. Int J Eat Disord (2015) 
48:397–405. doi:10.1002/eat.22283 
40. Kato H, Matsuda K, Baba K, Shimosegawa E, Isohashi K, Imaizumi M, et al. 
MR imaging-based correction for partial volume effect improves detectability 
of intractable epileptogenic foci on iodine 123 iomazenil brain SPECT images: 
an extended study with a larger sample size. AJNR Am J Neuroradiol (2012) 
33:2088–94. doi:10.3174/ajnr.A3121 
41. Kato H, Shimosegawa E, Oku N, Kitagawa K, Kishima H, Saitoh Y, et al. MRI-
based correction for partial-volume effect improves detectability of intractable 
epileptogenic foci on 123I-iomazenil brain SPECT images. J Nucl Med (2008) 
49:383–9. doi:10.2967/jnumed.107.046136 
Conflict of Interest Statement: The authors declare that the research was con-
ducted in the absence of any commercial or financial relationships that could be 
construed as a potential conflict of interest.
The Reviewer, JK, and handling Editor, GH, declared their shared affiliation, and 
the handling Editor states that the process nevertheless met the standards of a fair 
and objective review.
Copyright © 2016 Nagamitsu, Sakurai, Matsuoka, Chiba, Ozono, Tanigawa, 
Yamashita, Kaida, Ishibashi, Kakuma, Croarkin and Matsuishi. This is an open- access 
article distributed under the terms of the Creative Commons Attribution License (CC 
BY). The use, distribution or reproduction in other forums is permitted, provided the 
original author(s) or licensor are credited and that the original publication in this 
journal is cited, in accordance with accepted academic practice. No use, distribution 
or reproduction is permitted which does not comply with these terms.
